Latest Convertible Notes News

AVA Risk Group has locked in a strategic investment of up to A$12.6 million from US-based Hale Capital, aiming to boost its footprint in the lucrative US critical infrastructure market. The deal includes convertible notes and warrants priced at an 81% premium, alongside a new board appointment.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Enlitic has locked in commitments for an A$8 million convertible note capital raise, with initial funds arriving immediately and the remainder pending shareholder approval. This funding aims to extend the company’s runway as it advances its AI-driven healthcare solutions.

Jayride Group Limited reports a reduced quarterly loss and secures fresh capital, yet faces ongoing uncertainty over its ability to continue as a going concern during its ASX reinstatement process.

JAYRIDE Group has amended its quarterly cash flow report to correct classification errors, while outlining plans for a new SaaS platform rollout and potential capital raising to support operations.

Native Mineral Resources Holdings has locked in a $3 million convertible note raising from Lind Global Fund III LP, with the option to access up to $10 million. The funding aims to bolster working capital and support growth in the Charters Tower region.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Global Uranium and Enrichment Limited (GUE) has registered its scheme booklet with ASIC, detailing the proposed acquisition by Snow Lake Resources Ltd. The independent expert report supports the fairness and reasonableness of the deal, with GUE directors unanimously recommending shareholder approval.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.